Tokyo, Feb. 28 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060775) titled 'Nova-sTAR PIONEER-JP-Panel Interview of ONcology practice with Experience of TAR-200 in Japan' on Feb. 27.
Study Type:
Observational
Primary Sponsor:
Institute - Janssen Pharmaceutical K.K.
Condition:
Condition - Bladder cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To describe early experiences regarding TAR-200 insertion, removal, and patient care from physicians with experience treating patients with TAR-200 in clinical trials. Based on the findings, the study aims to identify clinical best practices, barriers, and future care models to support the appropriate use of TAR-200.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Physicians who meet the following criteria:
1.Had experience of treatment with TAR-200 in HR-NMIBC and/or MIBC patients in clinical trials.
2.Provided consent to participate in the interview and/or roundtable discussion.
Key exclusion criteria - None
Target Size - 15
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 01 Month 29 Day
Date of IRB - 2026 Year 02 Month 19 Day
Anticipated trial start date - 2026 Year 02 Month 20 Day
Last follow-up date - 2026 Year 06 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069491
Disclaimer: Curated by HT Syndication.
